Avenda Health, a startup focused on personalized prostate cancer care, recently received 510(k) clearance from the FDA for its cancer mapping platform. The platform uses a patient’s own diagnostic data to define the extent of the disease and create a cancer probability map with optimal treatment margins.
CAR-T has become increasingly recognized as an exciting and potentially paradigm-shifting treatment in the past five years. In fact, more than 10,000 patients have undergone this new treatment for certain types of leukemia, lymphoma and multiple myeloma.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
With a global epidemic of obesity and diabetes and their known relationship to cancer, researchers and oncologists are turning their attention to metabolic hormones as promising new targets for cancer treatment.
The MedCity CONVERGE conference at the University City Science Center June 19 in Philadelphia will be the scene of a dynamic series of conversations around cancer treatment, precision medicine, value-based care and investment trends. It will spotlight industry experts, presentations from innovative startups and collaborations.
Engineering researchers at the University of Michigan have developed a battery-operated injectable computer with a radio antenna that can transmit data to a device located up to 12 inches outside of the body.
So where are we with CAR-T? Is it the innovative, transformative, disruptive, paradigm-changing cancer therapy we all hope for, or is it another incremental improvement?
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Patients with previously treated advanced renal cell carcinoma have a new treatment option with cabozantinib — a kinase inhibitor shown to improve overall survival compared to everolimus, as a Cleveland Clinic researcher noted at ASCO 2016 over the weekend.
The FDA issued an alert about the drug on Monday, and in the warning it warned healthcare professionals that the drug is not approved for previously untreated chronic lymphocytic leukemia.
Oncora Medical's approach provides clinical decision support for radiation oncologists to reduce radiation toxicity and guide more personalized treatments.
Under the terms of the agreement, Onxeo is acquiring DNA Therapeutics for an upfront payment of nearly $1.85 million in common shares at deal closing.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Future topics will include lower back pain, ADHD and type 2 diabetes.
Medtronic takes over the OsteoCool device for treating cancers that metastasize to the spine, created by Baylis Medical.
The startup created from Dana-Farber Cancer Institute announced today the closing of a $73 million Series A round of financing and a promising partnership with Roche.
Flagship Ventures has launched new company Evelo Therapeutics, which will be using an understanding of the microbiome to created targeted cancer treatment.
Patients who have recurrent or metastatic solid tumors that are not responding to standard treatment could soon receive helpful treatment with the help of a GSK and Merck joined effort.